US drug labels to warn of risks of combining opioids and benzodiazepines
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4784 (Published 02 September 2016) Cite this as: BMJ 2016;354:i4784- Michael McCarthy
- Seattle
The US Food and Drug Administration is demanding changes to the labels for prescription opioid and benzodiazepine products to include warnings of the risks of profound sedation, respiratory suppression, coma, and death when these drugs are used in combination.1
FDA commissioner Robert Califf said that the agency was taking the action in response to the substantial increase in overdoses seen in patients taking opioids and benzodiazepines together. He said, “We implore healthcare professionals to heed these new warnings and more …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.